Lightnews — Scholar-powered news

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 7

Look mom! I am on Bluesky ☺️ #ERA25

Jayana Devathasan @jyndvthsn.bsky.social · Jun 7

Social media as a tool for spreading kidney health from @hdiniz.bsky.social #era25 #inception

8

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 7

Thank you so much for attending and sharing our session 🤩
Next time, come say hi 👋

1

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Yeah. Hopefully the group with HFrEF gets some benefit 🤞

4

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Electronic Communication Committee getting their diplomas of merit at the Presidential dinner from the President Prof. @rosertorra.bsky.social #ERA25 ☺️

1 5

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Yes @lonniepyne.bsky.social was the presenter! Hopefully he might sneak in to give his thoughts on the matter #ERA25

1 1

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Also, the last author presented a new meta analysis with ACHIEVE and ALCHEMIST. Considering only studies with low risk of bias, still no evidence of positive effect @hswapnil.medsky.social

1

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

So, about that. @pepasolerr.bsky.social asked about stratification by LVEF/echo data. Looks like only a small % had echo at baseline, but during follow up most patients got one. The author said they are going to look into that #ERA25

1 1 2

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Sorry, the app might have bugged on me. Are you talking about the Spironolactone trial? This replies are under the sglt2i aki analysis

1

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Me neither, but the study was well designed to answer the question. Regarding HF, I don't think so, but they basically used all the Empagliflozin trials for the analysis

1 1

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Prof Anders made a case for the (im)balance between workload (hyperfiltration) and nephron mass as the key interaction

DM is a risk factor - there are no diabetic HF or diabetic cerebral vascular disease. Most cases are probably multifactorial

HTN ckd probably doesnt exist and most are genetic

1 1 2

Reposted by Hugo Diniz, MD 🇵🇹🇪🇺

Jayana Devathasan @jyndvthsn.bsky.social · Jun 6

Vlado Perkovic discussing Sibeprenlimab (APRIL binder) at Late Breaking Clinic Trials II at #era25. Great to see Oceanians (Aus/NZers) on stage!

1 1 8

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Wasn't aware of that, thanks! Dr. Walsh mentioned it is already accepted for publication in a major journal #ERA25

2

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

ACHIEVE trial - Spironolactone in Hemodialysis stopped early... due to futility 😢

I had some hopes for this one.
#ERA25

2 11 22

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

iSGLT2 effects on Acute Kidney Outcomes #ERA25

✅ Clear protective effects for AKI
❌ No extra risk of AKI events during the acute eGFR dip

1 3 17

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Sibeprenlimab in IgA Nephropathy #ERA25
* Data presented is the 9-month reduction in proteinuria

1 3

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 6

Visionary interim analysis! #ERA25 massive reduction in proteinuria after 1 year of treatment

1 5

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 5

Thanks for letting me know 🙏

1

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 5

Reduce the Workload, save your kidneys #ERA25

1 4

Reposted by Hugo Diniz, MD 🇵🇹🇪🇺

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Jun 5

I agree.

Clinically it doesn’t hurt to try a flozin if a patient with diabetes or HF is on an MRA and has hyperkalemia since flozins are clearly indicated in that patient population

But don’t bank on them to fix the issue - it’s a small effect even if true!

#ERA25 #NephSky

1 2 8

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 5

In a bit more detail... #ERA25

1 1 5

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 5

Prof. Anders starting with a banger

Diabetic Kidney Disease and Hypertensive Kidney Disease don't exist! 😱 #ERA25

3 1 13

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 5

Ah, yes. By the way they presented it looked significant. But, still a small decrease is much better than an increased risk 😁

a glass half full of blue liquid on a gray background

ALT: a glass half full of blue liquid on a gray background

media.tenor.com

1

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 5

Yes, the lack of morphological and hemodynamic data about the AVGs was also puzzling #ERA25

Hugo Diniz, MD 🇵🇹🇪🇺 @hugodiniz.medsky.social · Jun 5

#ERA25

1

Reposted by Hugo Diniz, MD 🇵🇹🇪🇺

Alex Meraz @nephroguy.bsky.social · Jun 5

@kevinyau.bsky.social GLP1 agonist master Jedi presenting at #ERA25.

💉GLP1 agonist reduce ED visits and hospitalizations!!!

📉Awesome methods. Best of the session:

💊DDP4 for comparison, IPTW, ICES data. Ticking all the right boxes (EPI nerd).

💊Only 40% on SGLT2i!!! We should flozinate more!!!

3 4 9